Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligand recognized is sialyl-Lewis X.
Mediates rapid rolling of leukocyte rolling over vascular surfaces during the initial steps in inflammation through interaction with SELPLG. Mediates cell-cell interactions and cell adhesion via the interaction with integrin alpha-IIb/beta3 (ITGA2B:ITGB3) and integrin alpha-V/beta-3 (ITGAV:ITGB3) (PubMed:37184585)
Interacts with SNX17. Interacts with SELPLG/PSGL1 and PODXL2 and mediates neutrophil adhesion and leukocyte rolling. This interaction requires the sialyl-Lewis X epitope of SELPLG and PODXL2, and specific tyrosine sulfation on SELPLG.
Interacts (via C-type lectin domain) with alpha-IIb/beta3 integrin ITGA2B:ITGB3 and alpha-V/beta-3 integrin ITGAV:ITGB3 (PubMed:37184585). Interacts with alpha5/beta1 integrin ITGA5:ITGB1 and alpha4/beta1 integrin ITGA4:ITGB (PubMed:37184585)
Stored in the alpha-granules of platelets and Weibel-Palade bodies of endothelial cells. Upon cell activation by agonists, P-selectin is transported rapidly to the cell surface
The C-type lectin domain is required for binding to integrins (PubMed:37184585). Binding to soluble integrins alpha-V/beta-3 (ITGAV:ITGB3) and alpha-IIb/beta3 (ITGA2B:ITGB) is cation-dependent in order of preference of 1 mM Mn(2+) > Mg(2+) > Ca(2+) (PubMed:37184585). Binds to the allosteric site (site 2) of integrins and activates them (PubMed:37184585).
The interaction with integrins may mediate cell-cell interactions and cell adhesion (PubMed:37184585)
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to SELPLG, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 30
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT03938454 | Priapism | A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism | PHASE2 | COMPLETED |
| NCT01895725 | Cardiovascular Risk Factors, Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease | Correlation of Artherosclerotic Plaque Volume and Intima Media Thickness With Soluble P-selectin | N/A | ACTIVE_NOT_RECRUITING |
| NCT05864079 | Overweight and Obesity | Developmental Endothelial Locus-1, Platelet Count, and Soluble P-selectin in Overweight and Obese Subjects | N/A | COMPLETED |
| NCT03812328 | Venous Thromboembolism | Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement | PHASE2 | COMPLETED |
| NCT04505774 | Covid19 | Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE | PHASE4 | COMPLETED |
| NCT04540042 | Asthma, Chronic Obstructive Pulmonary Disease | Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2) | PHASE2 | COMPLETED |
| NCT03474965 | Sickle Cell Disease (SCD) | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | PHASE2 | COMPLETED |
| NCT02896543 | Acute Myocardial Infarction | The Relationship of Change of Dendritic Cells Fractalkine and P-selectin Patients With Acute Myocardial Infarction | N/A | COMPLETED |
| NCT02649660 | Fabry Disease | Lipidomics and Functional Analyses of Platelets in Fabry Disease | N/A | UNKNOWN |
| NCT04662931 | Sickle Cell Disease (SCD) | An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients | PHASE4 | COMPLETED |